Yu H B, Wu W J, Lv X M, Shi Y, Zheng L, Zhang J G
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Oct 18;52(5):919-923. doi: 10.19723/j.issn.1671-167X.2020.05.021.
To investigate the clinical application and efficacy of Ⅰ radioactive seeds implantation in the treatment of recurrent salivary gland carcinoma after external radiotherapy.
From July 2004 to July 2016, 43 cases of recurrent salivary gland carcinoma of the neck after external radiotherapy or surgery combined with external radiotherapy were treated. According to the conventional segmentation radiotherapy for head and neck cancer (once a day, 1.8-2.0 Gy each time, 5 days per week), the cumulative radiation dose of the patients in this group was calculated. In the study, 26 patients received 50-60 Gy, 7 patients received less than 50 Gy, 4 patients received 60-70 Gy, and 6 patients received more than 80 Gy (range: 80-120 Gy). The interval between the last external irradiation and local recurrence was 4-204 months, and the median interval was 48 months. Among them, 25 cases were treated with Ⅰ radioactive seeds implantation only and 18 cases were treated with Ⅰ radioactive seeds implantation after operation. The prescription dose was 100-140 Gy. The control rate, survival rate and disease-free survival rate were recorded to evaluate the side effects.
The median follow-up time was 27 months (ranging from 2.5 to 149.0 months). Among them, the median follow-up time of adenoid cystic carcinoma patients was 31 months (range: 2.5-112.0 months), and the median follow-up time of mucoepidermoid carcinoma patients was 18 months (range: 5-149 months). The local control rates for 1, 3 and 5 years were 66.5%, 48.8% and 42.7%, respectively. The 1-, 3- and 5- year survival rates were 88.0%, 56.7% and 45.8%, respectively. The disease-free survival rates of 1, 3 and 5 years were 58.3%, 45.4% and 38.1%, respectively. There was no statistically significant difference in local control rate, survival rate, and disease-free survival between the radioactive seeds implantation group and the radioactive seeds implantation group after surgical resection. There were 2 cases of acute radiation reaction Ⅰ/Ⅱ and 3 cases of reaction Ⅲ or above. In the late stage of radiotherapy, there were 8 cases with Ⅰ/Ⅱ grade reaction and 3 cases with Ⅲ grade or above reaction. The incidence of radiation reactions of Grade Ⅲ and above was 7%.
Ⅰ radioactive seeds implantation provides an alternative method for the treatment of recurrent salivary gland carcinoma after external radiotherapy. The local control rate and survival rate are improved on the premise of low incidence of side effects.
探讨¹²⁵I放射性粒子植入治疗外照射后复发性涎腺癌的临床应用及疗效。
选取2004年7月至2016年7月间收治的43例外照射或手术联合外照射后颈部复发性涎腺癌患者。按照头颈癌常规分割放疗方案(每日1次,每次剂量1.8 - 2.0 Gy,每周5次),计算该组患者的累积放疗剂量。研究中,26例患者接受50 - 60 Gy照射,7例患者接受剂量小于50 Gy,4例患者接受60 - 70 Gy照射,6例患者接受剂量大于80 Gy(范围:80 - 120 Gy)。末次外照射至局部复发间隔时间为4 - 204个月,中位间隔时间为48个月。其中,25例仅行¹²⁵I放射性粒子植入治疗,18例行¹²⁵I放射性粒子植入术后治疗。处方剂量为100 - 140 Gy。记录控制率、生存率及无病生存率,评估副作用。
中位随访时间为27个月(范围:2.5 - 149.0个月)。其中,腺样囊性癌患者中位随访时间为31个月(范围:2.5 - 112.0个月),黏液表皮样癌患者中位随访时间为18个月(范围:5 - 149个月)。1年、3年和5年局部控制率分别为66.5%、48.8%和42.7%。1年、3年和5年生存率分别为88.0%、56.7%和45.8%。1年、3年和5年无病生存率分别为58.3%、45.4%和38.1%。放射性粒子植入组与手术切除后放射性粒子植入组在局部控制率、生存率及无病生存率方面差异无统计学意义。急性放射性反应Ⅰ/Ⅱ级2例,Ⅲ级及以上反应3例。放疗晚期,Ⅰ/Ⅱ级反应8例,Ⅲ级及以上反应3例。Ⅲ级及以上放射性反应发生率为7%。
¹²⁵I放射性粒子植入为外照射后复发性涎腺癌提供了一种可供选择的治疗方法。在副作用发生率较低的前提下,提高了局部控制率和生存率。